A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates

While the rapid development of COVID-19 vaccines has been a scientific triumph, the need remains for a globally available vaccine that provides longer-lasting immunity against present and future SARS-CoV-2 variants of concern (VOCs). Here, we describe DCFHP, a ferritin-based, protein-nanoparticle vaccine candidate that, when formulated with aluminum hydroxide as the sole adjuvant (DCFHP-alum), elicits potent and durable neutralizing antisera in non-human primates against known VOCs, including Omicron BQ.1, as well as against SARS-CoV-1. Following a booster ∼one year after the initial immunization, DCFHP-alum elicits a robust anamnestic response. To enable global accessibility, we generated a cell line that can enable production of thousands of vaccine doses per liter of cell culture and show that DCFHP-alum maintains potency for at least 14 days at temperatures exceeding standard room temperature. DCFHP-alum has potential as a once-yearly booster vaccine, and as a primary vaccine for pediatric use including in infants.

[1]  B. Gunn,et al.  Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers , 2022, Science Translational Medicine.

[2]  D. Follmann,et al.  A Covid-19 Milestone Attained - A Correlate of Protection for Vaccines. , 2022, The New England journal of medicine.

[3]  E. Wood,et al.  Monoclonal antibody levels and protection from COVID-19 , 2022, medRxiv.

[4]  J. Do,et al.  Simplified Purification of Glycoprotein-Modified Ferritin Nanoparticles for Vaccine Development , 2022, Biochemistry.

[5]  G. Alter,et al.  Correlates of protection against SARS‐CoV‐2 infection and COVID‐19 disease , 2022, Immunological reviews.

[6]  M. Gale,et al.  Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity , 2022, Cell.

[7]  Mark M. Davis,et al.  Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination , 2022, Cell.

[8]  Gregory D. Gromowski,et al.  A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge , 2021, NPJ vaccines.

[9]  Monzurul A. Roni,et al.  Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines , 2021, Vaccines.

[10]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[11]  B. Pulendran,et al.  Adjuvanting a subunit COVID-19 vaccine to induce protective immunity , 2021, Nature.

[12]  Rebecca Wang,et al.  Accelerating and de‐risking CMC development with transposon‐derived manufacturing cell lines , 2021, Biotechnology and bioengineering.

[13]  J. Cohen,et al.  Reinfection with SARS-CoV-2: Implications for Vaccines , 2020, Clinical Infectious Diseases.

[14]  D. Lauffenburger,et al.  Correlates of Protection Against SARS-CoV-2 in Rhesus Macaques , 2020, Nature.

[15]  W. Chiu,et al.  A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice , 2020, bioRxiv.

[16]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[17]  Ilya J. Finkelstein,et al.  Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes , 2020, bioRxiv.

[18]  J. Bloom,et al.  Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays , 2020, bioRxiv.

[19]  Philip L. Felgner,et al.  A serological assay to detect SARS-CoV-2 seroconversion in humans , 2020, medRxiv.

[20]  P. Wilson,et al.  Harnessing immune history to combat influenza viruses. , 2018, Current opinion in immunology.

[21]  R. Kelly,et al.  Generation of High Expressing Chinese Hamster Ovary Cell Pools Using the Leap-In Transposon System. , 2018, Biotechnology journal.

[22]  D. Agard,et al.  MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy , 2017, Nature Methods.

[23]  David J. Fleet,et al.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.

[24]  J. Mascola,et al.  Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. , 2013, The Journal of infectious diseases.

[25]  J. Whittle,et al.  Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies , 2013, Nature.

[26]  B. Antonsson,et al.  Differences in the glycosylation of recombinant proteins expressed in HEK and CHO cells. , 2012, Journal of biotechnology.

[27]  C. Frye,et al.  Improving the efficiency of CHO cell line generation using glutamine synthetase gene knockout cells , 2012, Biotechnology and bioengineering.

[28]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..